13-[5-[(4-Fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]-11-hydroxy-2-methyl-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 13-[5-[(4-Fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]-11-hydroxy-2-methyl-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione
• 英文别名: 13-[5-[(4-fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]-11-hydroxy-2-methyl-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione
• 化学式: C₂₀H₁₈FN₅O₄S
• 分子量: 443.5
• InChiKey: LSEQRJJVGFOIAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES
  申请人：Shionogi & Co., Ltd.

  公开号：US20200247818A1

  公开（公告）日：2020-08-06

  The present invention provides industrially suitable processes for preparing intermediates in the production of substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity. In the process as shown below, wherein each symbol is as defined in the specification, an optically active substituted tricyclic pyridone derivative of the formula (VII) is obtained in high yield and high enantioselectivity by subjecting a compound of the formula (III) or (VI) to intramolecular cyclization with controlling stereochemistry to obtain a compound of the formula (IV) having a removable functional group on an asymmetric carbon, and then removing the functional group thereof.

  本发明提供了在制备具有依赖CAP末端核酸酶抑制活性的取代多环吡啶酮衍生物的生产中的工业适用过程。在下面所示的过程中，其中每个符号如规范中定义，通过将式（III）或（VI）的化合物经过控制立体化学的分子内环化得到具有可移除手性碳上的可移除官能团的式（IV）的化合物，然后去除其官能团，以高产率和高对映选择性获得式（VII）的手性取代三环吡啶酮衍生物。
• [EN] 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS<br/>[FR] DÉRIVÉS 4-PYRIDINONETRIAZINES EN TANT QU'INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099586A1

  公开（公告）日：2014-06-26

  The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.

  本发明涉及公式(I)的4-吡啶酮三嗪衍生物；及其在药学上可接受的盐，其中A、X、Y、R1、R2、R3和R5如本文所定义。本发明还涉及包含至少一种4-吡啶酮三嗪衍生物的组合物，并且使用这些4-吡啶酮三嗪衍生物来治疗或预防受试者的HIV感染的方法。
• 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150329539A1

  公开（公告）日：2015-11-19

  The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R 1 , R 2 , R 3 and R 5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.
• US9714243B2
  申请人：——

  公开号：US9714243B2

  公开（公告）日：2017-07-25